Key result
In head and neck cancer patients undergoing concurrent chemoradiotherapy with cisplatin, the incidence of thromboembolic events was 1.9%, with a high Khorana score significantly associated with TEE risk.
Why the study?
The risk of thromboembolic events is higher in cancer patients, particularly those receiving cisplatin-based chemotherapy, than in the general population.
Cohort (n=257)
No
The incidence of thromboembolic events in head and neck cancer patients undergoing concurrent chemoradiotherapy with cisplatin is relatively low (1.9%), but patients with a higher Khorana score require closer surveillance.
Background The risk of thromboembolic events (TEE) in cancer patients, especially those receiving cisplatin-based chemotherapy, is higher than that of general population. Methods The study investigated the incidence of TEE in 257 head and neck (H&N) cancer patients, during or within 6 months of completion of concurrent chemoradiotherapy (CCRT) with cisplatin, and analyzed factors affecting TEE occurrence. Results TEE occurred in 5 patients, an incidence rate of 1.9%. Khorana score was the only factor associated with TEE occurrence ( p = 0.010). Conclusions The incidence of TEE in H&N cancer patients who underwent CCRT with cisplatin was relatively low when compared to other types of cancer. However, patients with a high Khorana score require more careful surveillance for possible TEE occurrence.
No takes yet. Share an insight, caveat, or question.
Cho et al. (2021) conducted a cohort in Head and neck cancer (n=257). Concurrent chemoradiotherapy with cisplatin was evaluated on Incidence of thromboembolic events (TEE). In head and neck cancer patients undergoing concurrent chemoradiotherapy with cisplatin, the incidence of thromboembolic events was 1.9%, with a high Khorana score significantly associated with TEE risk.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: